Salud financiera de hoja de balance de BioPorto

Salud financiera controles de criterios 6/6

BioPorto tiene un patrimonio de los accionistas total de DKK60.2M y una deuda total de DKK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son DKK89.8M y DKK29.7M respectivamente.

Información clave

Ratio deuda-patrimonio

kr.0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr.66.40m
Patrimonio	kr.60.16m
Total pasivo	kr.29.65m
Activos totales	kr.89.81m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Dec 25

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jun 28

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Feb 27

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

Oct 19

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

Jun 15

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK82.3M) de BIOPOR superan a sus pasivos a corto plazo (DKK25.4M).

Pasivo a largo plazo: Los activos a corto plazo de BIOPOR (DKK82.3M) superan a sus pasivos a largo plazo (DKK4.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BIOPOR está libre de deudas.

Reducción de la deuda: BIOPOR no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BIOPOR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: BIOPOR dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 8.6% cada año.

Salud financiera de hoja de balance de BioPorto

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Recent updates

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New 90-day high: kr.6.24

New 90-day high: kr.4.07

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Third quarter 2020 earnings released: kr.0.09 loss per share

Earnings beat expectations, revenue disappoints

BioPorto A/S, Annual General Meeting, Apr 29, 2021